VM 106

N/A

Report date: 2025/03/26 20:01:25

Base Information

Drug NameVM 106

Drug Alias NameNADPH oxidase subunit gene therapyVM-106

ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Stem cell therapy > Hematopoietic stem cells therapyCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Retroviral vector

Mechanisms of ActionNADPH oxidase modulators

TargetsNADPH oxidase

Therapy Area/IndicationsGranulomatous Disease, Chronic

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySouth Korea

CombinationsNo

Global Highest StatusDiscontinued (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesViromed

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesHelixmith Co Ltd

Active IndicationsN/A

Inactive IndicationsGranulomatous Disease, Chronic

Other Information

ATC CodeN/A